$1.18
Today
as of Jul 22, 16:52 ET
Last 30 days
Recent Press Releases & News
Preclinical Data for OPKO Biologics' OPK8801001 in Acromegaly Presented at ENDO 2026
Assessing OPKO Health (OPK) Valuation After Expanded Nicoya RAYALDEE Partnership In Greater China
How Investors May Respond To OPKO Health (OPK) Boosting Its Nicoya Stake And RAYALDEE Milestones
Overview
52-week range
$0.98
$1.60
32% of range
Avg surprise (last 2)
-62.5%
Avg reaction (last 1)
-1.4%
0% positive
Latest IV / EM
253%
EM ±57.9% · $1 · Aug 21
Earnings trends
EPS — actual vs estimate
Actual Estimate
Revenue vs Net Income
Revenue Net income
Earnings history
| Date | Period | Actual EPS | Est | Surprise | YoY %Δ | Day react | Source |
|---|---|---|---|---|---|---|---|
| Tue Mar 31, 2026 | Mar 2026 | $-0.07 | — | — | — | — | financials |
| Tue Sep 30, 2025 | Sep 2025 | $0.03 | — | — | — | — | financials |
| Thu Jul 31, 2025 | Jun/2025 | $-0.19 | $-0.12 | -58.3% | — | — | earnings |
| Wed Apr 30, 2025 | Mar/2025 | $-0.10 | $-0.06 | -66.7% | — | -1.4% | earnings |
| Mon Sep 30, 2024 | Sep 2024 | $0.03 | — | — | — | — | financials |
| Sun Jun 30, 2024 | Jun 2024 | $-0.01 | — | — | — | — | financials |
| Sat Sep 30, 2023 | Sep 2023 | $-0.11 | — | — | — | — | financials |
Upcoming
| Date | Fiscal | Time | EPS Est | LY EPS | YoY %Δ |
|---|---|---|---|---|---|
| Thu Jul 30, 2026 | Jun/2026 | OTHER | -$0.08 | -$0.19 | +57.9% |
Financials
Income statement (quarterly)
| Metric | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $124M | — | $152M | $157M | $150M | — | $174M | $182M |
| Cost of revenue | $78M | — | $102M | $107M | $107M | — | $134M | $131M |
| Gross profit | $46M | — | $50M | $49M | $43M | — | $40M | $52M |
| Operating income | $-51M | — | $48M | $-60M | $-67M | — | $-67M | $-62M |
| Net income | $-55M | — | $22M | $-148M | $-68M | — | $25M | $-10M |
| EPS (diluted) | $-0.07 | — | $0.03 | $-0.19 | $-0.10 | — | $0.03 | $-0.01 |
Balance sheet (quarterly)
| Metric | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 |
|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $332M | $364M | $412M | $267M | $429M | $427M | $400M | $41M |
| Inventory | $64M | $66M | $65M | $66M | $64M | $57M | $59M | $60M |
| Total current assets | $535M | $582M | $627M | $583M | $738M | $662M | $630M | $358M |
| Total assets | $1.86B | $1.93B | $2.00B | $1.97B | $2.13B | $2.20B | $2.26B | $1.98B |
| Long-term debt | $2M | $2M | $3M | $3M | $3M | $3M | $4M | $4M |
| Total liabilities | $652M | $664M | $690M | $676M | $817M | $835M | $853M | $585M |
| Total equity | $1.20B | $1.27B | $1.31B | $1.30B | $1.31B | $1.37B | $1.40B | $1.40B |